Guardant Health (GH) Projected to Post Earnings on Thursday

Guardant Health (NASDAQ:GH) is anticipated to announce its earnings results after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.75) per share and revenue of $192.50 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Guardant Health Trading Up 0.3 %

Shares of Guardant Health stock opened at $48.27 on Wednesday. Guardant Health has a twelve month low of $15.81 and a twelve month high of $50.89. The stock has a market capitalization of $5.96 billion, a P/E ratio of -11.38 and a beta of 1.32. The business’s fifty day moving average price is $39.51 and its 200 day moving average price is $31.27.

Insider Activity at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares of the company’s stock, valued at $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 2,652 shares of company stock valued at $93,192 over the last three months. 5.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have commented on the company. Guggenheim reissued a “buy” rating on shares of Guardant Health in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. raised their price objective on Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Sanford C. Bernstein cut their price objective on Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 30th. Barclays assumed coverage on Guardant Health in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price objective on the stock. Finally, The Goldman Sachs Group raised their price objective on Guardant Health from $36.00 to $49.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Sixteen investment analysts have rated the stock with a buy rating, According to MarketBeat, Guardant Health presently has a consensus rating of “Buy” and an average price target of $42.63.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.